Navigation Links
Regenerative medicine: Clinical trials launched for the treatment of delayed union fractures
Date:1/9/2013

The clinical trials aim to repair bones using adult stem cells combined with biomaterials. It will be conducted in France in the Crteil University Hospital Centre and the Regional University Hospital Centre in Tours, in collaboration with the French Blood Establishment.

The REBORNE project began three years ago and its originality lies in using mesenchymal stem cells (MSC), found in bone marrow, to help heal fractures. Adult stem cells are amplified in culture, then are associated with biomaterial before being implanted on the fracture. Promising pre-clinical trials have now paved the way for the launch of these new clinical trials.

Following trauma (fall or road accident), there is a high incidence of delayed union or non-union in tibia, femur or humerus bones requiring a surgical apposition of an autologous bone graft (patient's own bone). However, the bone graft available is limited and complications are often observed at the second surgical site. The partners of the European project REBORNE propose an alternative treatment using autologous mesenchymal stem cells associated with a synthetic bone substitute. Thanks to a bone marrow aspiration under local anaesthesia, the mesenchymal stem cells are isolated and amplified in culture for 21 days. During the surgical intervention stem cells are associated with biphasic calcium phosphate ceramic granules and implanted at the site of the fracture. In this way, the biomaterial is used as "scaffolding" and encourages stem cell proliferation. The stem cells are then differentiated into bone cells and regenerate the bone tissue around the fracture. The French Medicinal Agency ANSM gave its green light on 3 January 2013 so that these Inserm-sponsored trials can now begin in France, with seven patients receiving treatment in the Crteil University Hospital Centre and the Regional University Hospital Centre in Tours. Ultimately, thirty patients will be included in France, Spain, Germany and Italy to be
'/>"/>

Contact: Pierre LAYROLLE
pierre.layrolle@inserm.fr
33-027-264-1143
INSERM (Institut national de la sant et de la recherche mdicale)
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Dr. Farshchian: Plica of the knee is now being treated with regenerative medicine at he center for regenerative medicine.
2. New company applies regenerative medicine to corneal transplantation
3. Dr. Farshchian: Advanced Osteoarthritis of the Knee is Now being Treated with Regenerative Medicine at The Center for Regenerative Medicine
4. Dr. Farshchian : The knee joint is now being treated with regenerative medicine at he center for regenerative medicine
5. Dr. Farshchian: Chronic Exertional Compartment Syndrome Now Treated at the Center for Regenerative Medicine
6. Dr. Farshchian: The Center for regenerative medicine introduces Genorthix system
7. Dr. Farshchian: Tibialis Posterior Dysfunction is Now Being Treated at The Center for Regenerative Medicine in Miami
8. Dr. Farshchian: Rotator Cuff Injuries are being Treated Now Using Cell Therapy at the Center for Regenerative Medicine
9. Dr. Farshchian: Trochanter Bursitis is Now Treated at the Center for Regenerative Medicine
10. Dr. Farshchian: New treatment on Muscle Atrophy, now available at the Center for Regenerative Medicine
11. Dr. Farshchian: Muscular Contusions are Now Being Treated Successfully at The Center for Regenerative Medicine in Miami
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... April 21, 2015 The joint venture ... it is opening its first freestanding emergency room later ... Arizona and will be licensed under Dignity Health Arizona ... Health and Adeptus Health joint venture. , Tim Bricker, ... Mercy Gilbert Medical Centers said the new facility will ...
(Date:4/21/2015)... April 21, 2015 Wireless Analytics, ... has been recognized by the Boston Business Journal as ... ranking was announced at a recent event celebrating the ... of the fastest-growing private companies in Massachusetts. , Wireless ... the state that recorded the fastest revenue growth from ...
(Date:4/21/2015)... The report “Dermatitis – ... on the therapeutic development for Dermatitis. ... new targets and MOAs to produce first-in-class ... is available @ http://www.rnrmarketresearch.com/dermatitis-pipeline-review-h1-2015-market-report.html . ... involved in the therapeutic development for Dermatitis ...
(Date:4/21/2015)... Edward Avalos, USDA Under Secretary for Marketing ... of the California Department of Food and Agriculture, have ... GrowRIVERSIDE Conference: The Future of Local Food, conference organizers ... nationally known experts intensifies an already strong line-up of ... slated to speak at the June 11-13 event. ...
(Date:4/21/2015)... Wojo Nutrition announces Abe’s ... its healthiest, will carry Wojo Nutrition's lines of single ... Nutrition, they’ve launched a revolution in the vitamin industry ... meet their multifaceted goals. Their line of single serving ... has been specially formulated to be as unique as ...
Breaking Medicine News(10 mins):Health News:Dignity Health and Adeptus Health to Open First Freestanding Emergency Room in Chandler, Arizona 2Health News:Dignity Health and Adeptus Health to Open First Freestanding Emergency Room in Chandler, Arizona 3Health News:Wireless Analytics Ranked as 25th Fastest Growing Private Company in Massachusetts 2Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 4Health News:USDA Under Secretary, former CA Agriculture Director to Address 2nd Annual “GrowRIVERSIDE” Conference in June 2Health News:USDA Under Secretary, former CA Agriculture Director to Address 2nd Annual “GrowRIVERSIDE” Conference in June 3Health News:Wojo Nutrition Announces their Lines of Single Serving Liquid Vitamins will be Available for Purchase online at Abesmarket.com Beginning in May 2
... growing evidence that supports an association between atypical fractures of ... without trauma and the use of bisphosphonates, drugs proven ... osteoporosis. While the risk for suffering an atypical femur fracture ... in 1,000 patients after six years of treatment research ...
... HealthDay Reporter , MONDAY, Feb. 6 (HealthDay News) -- ... the first line of defense is lifestyle changes such as ... lifestyle changes don,t get blood sugar levels under control, the ... the first oral treatment that should be given. ...
... Institute at Jefferson joint researchers continue to seek better ... (PJI) in patients following total joint arthroplasty. Their ... in diagnosing urinary tract infections, can also have a ... study built on previous work conducted by Javad Parvizi, ...
... By Serena Gordon HealthDay Reporter , MONDAY, ... the pancreas has sweet-taste receptors -- like those found on ... is a common ingredient in many foods and beverages. Nutrition ... fructose and the new findings might bolster their concerns. ...
... , MONDAY, Feb. 6 (HealthDay News) -- ... linked to a slightly increased risk of death, a ... it should be taken into account by doctors and ... The investigators analyzed the findings of 10 clinical ...
... by Van Andel Research Institute (VARI) scientists enables the ... glioblastoma the most common and most aggressive malignant ... January in the Proceedings of the National Academy ... signaling activation and gene amplification for their susceptibility to ...
Cached Medicine News:Health News:Halting bone-building osteoporosis drug use cuts risk for additional atypical femur fracture in half 2Health News:Metformin Preferred Drug for Type 2 Diabetes, Experts Say 2Health News:Metformin Preferred Drug for Type 2 Diabetes, Experts Say 3Health News:Rothman Institute at Jefferson research suggests use of LE strips to diagnose PJI 2Health News:Pancreas May 'Taste' Fructose, Hinting at Links to Diabetes 2Health News:Pancreas May 'Taste' Fructose, Hinting at Links to Diabetes 3Health News:Certain Cancer Drugs May Have Fatal Side Effects: Analysis 2Health News:Discovery predicts patient sensitivity to important drug target in deadly brain cancer 2
(Date:4/21/2015)... , April 21, 2015  The New York City ... LLP this week commenced two wrongful death lawsuits, each ... thinner Xarelto.  In each case it is alleged that ... fits all" for patients, and without a disclosure that ... once it starts. Both of the firm,s ...
(Date:4/21/2015)... Calif., April 21, 2015 Amgen (NASDAQ: ... quarter of 2015. Key results include: , Total ... 2014 to $5,033 million, with 12 percent product sales ... ® (denosumab), EPOGEN ® (epoetin alfa), Sensipar ... changes in foreign exchange rates impacted total revenue and ...
(Date:4/21/2015)... 2015  Perrigo Company plc ("Perrigo") (NYSE: PRGO ... has unanimously rejected the unsolicited Proposal (the "Proposal") from ... 8, 2015, to acquire all of the outstanding shares ... review, advised by its financial and legal advisors, the ... Company and its future growth prospects and is not ...
Breaking Medicine Technology:Law Firm Starts Two Suits for Deaths of Users of Xarelto 2Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 2Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 3Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 4Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 5Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 6Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 7Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 8Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 9Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 10Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 11Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 12Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 13Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 14Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 15Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 16Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 17Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 18Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 19Perrigo Board Unanimously Rejects Unsolicited Proposal From Mylan 2Perrigo Board Unanimously Rejects Unsolicited Proposal From Mylan 3Perrigo Board Unanimously Rejects Unsolicited Proposal From Mylan 4Perrigo Board Unanimously Rejects Unsolicited Proposal From Mylan 5Perrigo Board Unanimously Rejects Unsolicited Proposal From Mylan 6Perrigo Board Unanimously Rejects Unsolicited Proposal From Mylan 7Perrigo Board Unanimously Rejects Unsolicited Proposal From Mylan 8Perrigo Board Unanimously Rejects Unsolicited Proposal From Mylan 9
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: